We assessed the effect of the vasodilating calcium channel blocker nitrendipine on glucose tolerance in young spontaneously hypertensive rats (SHR) (n=15). The nitrendipine group received 1 g/kg chow for 3 weeks. Untreated SHR (n = 14) served as controls. At 3 weeks body weight was comparable, whereas systolic blood pressure was 157±9 mm Hg in nitrendipine-treated rats versus 191 ±10 mm Hg in controls (mean±SD, P<.00001). Fasting glucose was 6.8±2.7 mmol/L in nitrendipine-treated versus 8.9±1.5 mmol/L in control rats (P<.03). An intravenous glucose tolerance test (300 mg/kg) showed plasma glucose levels at 2, 5, 15, and 30 minutes to be significantly lower in the nitrendipine-treated group versus controls (two-way ANOVA, P<.03). It has been suggested that insulin resistance may be due at least in part to hemodynamic factors. For example, the hyperinsulinemia of SHR is partly due to decreased insulin clearance, 4 -10 mostly across the kidneys and skeletal muscle. Interestingly, regional hemodynamic studies have revealed that these two organs have a markedly reduced blood flow. 11 Earlier studies have described a decreased number of small arterioles in SHR. This vascular rarefaction 12 could contribute to a decreased delivery of glucose and insulin to peripheral tissues in the animals. Indeed, a crucial step in the action of insulin in the dog is related to its tissue delivery across the capillaries. 13 Human studies have also indicated that insulin resistance could be related to an inability to appropriately increase muscle blood flow.
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Abstract We assessed the effect of the vasodilating calcium channel blocker nitrendipine on glucose tolerance in young spontaneously hypertensive rats (SHR) (n=15). The nitrendipine group received 1 g/kg chow for 3 weeks. Untreated SHR (n = 14) served as controls. At 3 weeks body weight was comparable, whereas systolic blood pressure was 157±9 mm Hg in nitrendipine-treated rats versus 191 ±10 mm Hg in controls (mean±SD, P<.00001). Fasting glucose was 6.8±2.7 mmol/L in nitrendipine-treated versus 8.9±1.5 mmol/L in control rats (P<.03). An intravenous glucose tolerance test (300 mg/kg) showed plasma glucose levels at 2, 5, 15, and 30 minutes to be significantly lower in the nitrendipine-treated group versus controls (two-way ANOVA, P<.03). Glucose utilization was estimated by the uptake of [ ) is reduced and its plasma half-life prolonged while plasma insulin levels are elevated. 5 It has been suggested that insulin resistance may be due at least in part to hemodynamic factors. For example, the hyperinsulinemia of SHR is partly due to decreased insulin clearance, 4 -10 mostly across the kidneys and skeletal muscle. Interestingly, regional hemodynamic studies have revealed that these two organs have a markedly reduced blood flow. 11 Earlier studies have described a decreased number of small arterioles in SHR. This vascular rarefaction 12 could contribute to a decreased delivery of glucose and insulin to peripheral tissues in the animals. Indeed, a crucial step in the action of insulin in the dog is related to its tissue delivery across the capillaries. 13 Human studies have also indicated that insulin resistance could be related to an inability to appropriately increase muscle blood flow. 14 The purpose of the present study was to test the hypothesis that insulin resistance in SHR is influenced by hemodynamic factors, such as reduced skeletal muscle blood flow. If true, one would expect that nitrendipine, 13 -16 a calcium channel blocker capable of increasing muscle blood flow, may correct or attenuate insulin resistance in addition to reducing blood pressure (BP 
Methods
SHR weighing approximately 150 g were obtained from the animal farm of the Tel Aviv University. They were housed in regular cages and maintained on a 12-hour light/dark cycle. They were fed grain regular chow (Kofflok) and had free access to tap water. The chow contained 56% grain-derived carbohydrate, 20% protein, 13% moisture, 5.5% cellulose, 3% fat, 0.8% calcium, 0.6% phosphorus, and 0.3% NaCl. Rats were weighed at weekly intervals, and their systolic BP was measured (prewarmed) by the tail-cuff method using a USM 105 BP recorder (Ueda Electronic Works). All animal housing and handling were in accordance with the guidelines and manual of the Committee on the Care of Laboratory Animals of the Hebrew University Hadassah School of Medicine.
After a week of habituation rats were divided into two groups: a control group (n = 14) (weight, 166±26 g) and a nitrendipine-treated group (n=15) (weight, 171±26 g). The drug was mixed daily with ground food (1 g/kg chow) and kept in a light-protected trough. After 3 weeks of treatment rats were anesthetized with ether, and PE-50 cannulas were inserted into the femoral artery and vein and exteriorized subcutaneously at the interscapular area. Cannulas were filled with heparinized saline solution (100 /iU/mL). Forty-eight hours later awake control rats were injected through the femoral vein catheter with a tracer dose of [ 3 H]DOG (2 jiCi/100 g body wt). Simultaneously, the rats were given a bolus injection of a glucose solution (50%, 300 mg/kg) for assessment of glucose tolerance. Arterial blood was collected from the femoral artery catheter for measurement of [ 3 H]DOG and glucose plasma levels.
Rats were decapitated 30 minutes after the injection, and blood was collected for measurement of glucose, [ 3 H]DOG, and insulin. Samples of spleen, heart, and striated muscle (gastrocnemius) were frozen in liquid nitrogen and used for tissue [ 3 H]DOG determination. 317 " 20 Uptake of [ 3 H]DOG by rat tissues was determined as originally described by Sokoloff et al, 17 Horn et al, 18 and us, per minute) was calculated as the negative least-squares natural logarithm of the plasma glucose concentration between 2 and 30 minutes after glucose administration. Means for controls and nitrendipine-treated SHR were compared by independent group Student's t test or the Mann-Whitney U test when appropriate. Intravenous glucose tolerance and plasma pHJDOG data were examined by two-way ANOVA as was BP by use of the CRUNCH statistical software package (CRUNCH Software Co). A value of P<.05 was considered statistically significant.
Results
Both nitrendipine and control SHR gained weight similarly throughout the experiment. As shown in Fig 1, nitrendipine prevented the increase in BP that occurred in control SHR [F(l,18)=57.17, />=.00001]; pairwise comparison showed that, at least during the final 2 weeks, BP was persistently lowered by nitrendipine (P< .00001).
Baseline glucose was significantly lower in nitrendipine SHR (6.8±2.7 mmol/L) than controls (8.9±1.5 mmol/L, P<.03). The results of the intravenous glucose tolerance test (Fig 2) show that nitrendipine SHR had lower plasma glucose levels throughout the test [F(l,25)=5.34, P<.03]. The glucose disappearance rate was higher (1.7±0.007 %/min) in nitrendipine than control SHR (1.1 ±0.008 %/min, P<.05). Baseline and postload insulin levels were not different between nitrendipine SHR and controls. The respective values for nitrendipine and controls at time 0 were 245 ±120 (40.8±20.0 MJ/mL) and 247±95 pmol/L (41.1 ±15.8 /i,U/mL) and, at 30 minutes, 276±156 (46±26 MU/mL) and 247±126 pmol/L (41+21 jiU/mL). . Thus, the significantly higher [ 3 H]DOG uptake in the heart and striated muscle of nitrendipine compared with control SHR (Fig  4) could not have been due to differences in clearance between the groups. These results are in contrast with the similar [ 3 H]DOG uptake in the spleen, which is an insulin-inert organ.
Discussion
In conformity with previous studies, nitrendipine treatment for 3 weeks significantly reduced the elevated BP in SHR. 15 ' 16 The salient finding in the present study is the markedly improved glucose tolerance in the nitrendipine-treated group compared with controls as evident from the significant difference in glucose disappearance rate between these groups. Unfortunately, blood samples for insulin were not drawn throughout the test because we were concerned with excessive blood loss. Nevertheless, in the presence of unchanged insulin at baseline and 30 minutes, the improved glucose tolerance in the nitrendipine group suggests an improved insulin sensitivity relative to the untreated controls. Moreover, both experimental 21 ' 22 and human 2325 studies show evidence that calcium channel blockers and specifically nitrendipine may reduce islet cell insulin secretion and the response to glucose load. This makes it unlikely that some of the improved glucose tolerance is due to increased peak insulin levels in the nitrendipine group. The increased [ 3 H]DOG uptake in the heart and striated muscle in nitrendipine SHR suggests that the improved glucose tolerance is the result of increased glucose uptake in this target tissue. It was shown by means of the hyperinsulinemic hyperglycemic clamp that in SHR the striated muscle is indeed the insulinresistant organ, whereas endogenous hepatic glucose production is normally regulated. 7 We have previously reported that [ 3 H]DOG uptake of heart and striated muscle is reduced in SHR compared with Wistar-Kyoto rats. 5 In the present study we have shown that [ 3 H]DOG uptake in SHR is improved with nitrendipine. Because the nitrendipine group had significantly lower BP than the control group, a possible effect of lower BP cannot be excluded. A search of the literature provided no information on the effect of antihypertensive agents on glucose tolerance or insulin sensitivity in SHR. It would be of interest to compare the effect of vasodilator and nonvasodilator drugs on glucose tolerance and insulin sensitivity in this rat model. In this context it is noteworthy that in human hypertensive patients the medications that do not adversely affect glucose metabolism are essentially the vasodilator agents, such as a-blockers, 31 It is therefore reasonable to suggest that at least part of the improvement in the glucose tolerance of nitrendipine-treated SHR may be related to nitrendipine-induced vasodilation. As transcapillary insulin delivery to tissue is critical for insulin action, 13 it may be relevant to the structural' 2 or functional hypertension-related abnormalities and their potential reversal by treatment. Insulin resistance of both hypertension and obesity 14 may be related to a subnormal increase in muscle blood flow in response to insulin. Vasodilators such as nitrendipine should have a beneficial effect in this regard by improving tissue insulin delivery and glucose tolerance.
In conclusion, the calcium channel entry blocker nitrendipine reduced BP and improved glucqse tolerance in SHR by increased muscle glucose uptake, presumably secondary to its vasodilator effects.
